BRISBANE, Calif., July 30 CA-InterMune-Present
BRISBANE, Calif., July 30 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and
President of InterMune, will present at the BMO Capital Markets 2008 Focus on
Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT.
To access a live audio webcast of the presentation, investors and other
interested parties may log on to the investor relations page of InterMune's
corporate website at http://www.intermune.com. The company recommends logging
on to the site 15 minutes prior to the start of the presentation in order to
register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development
and commercialization of innovative therapies in pulmonology and hepatology.
InterMune has a research and development portfolio addressing idiopathic
pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The
pulmonology portfolio includes the Phase 3 program, CAPACITY, which is
evaluating pirfenidone for the treatment of patients with IPF and a research
program focused on small molecules for pulmonary disease. The hepatology
portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to
as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor
research program, and a research program evaluating a new target in
hepatology. For additional information about InterMune and its R&D pipeline,
please visit http://www.intermune.com.
SOURCE InterMune, Inc.
